Abstract
Rationale & Objective Pregnancy complications are risk factors for cardiovascular diseases (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD.
Methods This study included 576 mothers of diverse ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and cystatin C were measured 1-3 days after delivery. CVD during follow-up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time-to-CVD events were assessed using Cox proportional hazards models.
Results During an average of 10.3±3.2 years of follow-up, 34 mothers developed one or more CVD events. Although no significant associations were found between creatinine and risk of CVD, per unit increase of cystatin C (CysC) was associated with a hazard ratio (HR) of 5.21 (95%CI = 1.49-18.2) for CVD. A borderline significant interactive effect was observed between elevated CysC (≥75th percentile) and preeclampsia. Compared to those without preeclampsia and with normal CysC level (<75th percentile), mothers with preeclampsia and elevated CysC had the highest risk of CVD (HR=3.8, 95%CI = 1.4-10.2), while mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery.
Conclusions In this sample of US, traditionally under-represented multi-ethnic high-risk mothers, elevated maternal plasma cystatin C and pregnancy complications synergistically increased risk of CVD later in life. These findings warrant further investigation.
Clinical Perspectives What is new?
Maternal postpartum elevated levels of cystatin C are independently associated with higher risk of cardiovascular diseases (CVD) later in life.
Maternal pregnancy complications coupled with postpartum elevated levels of cystatin C synergistically increased future risk of CVD.
What are the clinical implications?
These findings, if further confirmed, suggest that women with pregnancy complications and elevated postpartum cystatin C may be at particular high risk for CVD later in life compared to women without these risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03228875
Funding Statement
This work is supported by a grant from the NIH/OD Bench to Bedside and Back (BtB) Program (award# 996528). Dr Hong is partly supported by National Institutes of Health (NIH) grants (R21AI154233) and by the Johns Hopkins Population Center (NICHD P2CHD042854). Drs. Heymann J, Yoshida T and Kopp J are also supported by the Intramural Research Program, NIDDK, NIH under Z1A-DK043308. Dr. Winkler is supported in part by the National Institutes of Health and the National Cancer Institute Intramural Research Program (CAW) and under contract 75N91019D00024. The Boston Birth Cohort (the parent study) was supported in part by the National Institutes of Health (NIH) grants (2R01HD041702, R21HD066471, R01HD086013, R01HD098232, R01ES031272, and R01ES031521); and the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) (UT7MC45949). This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by any funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Boston Medical Center and the Johns Hopkins Bloomberg School of Public Health institutional review boards
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This is an ongoing cohort study. To ensure confidentiality of participants, the research data are not publicly available. However, the relevant data reported in this study is available upon reasonable request and after IRB review and approval
Non-standard Abbreviations and Acronyms
- AF
- Atrial fibrillation
- BBC
- Boston Birth Cohort
- BMI
- Body mass index
- CKD
- Chronic kidney disease
- CVD
- Cardiovascular disease
- CysC
- Cystatin C
- EMR
- Electronic medical records
- GFR
- Glomerular filtration rate
- HF
- Heart failure
- HR
- Hazard ratios
- IHD
- Ischemic heart disease
- IRB
- Institutional review board
- LOESS
- Locally weighted scatterplot smoothing
- PH
- Proportional hazards
- QC
- Quality control
- SD
- Standard deviation
